Xintela publishes Phase I/IIa data showing XSTEM improves pain, function in knee osteoarthritis study
Reuters2026/08/11 06:35- Xintela published peer-reviewed Phase I/IIa results for XSTEM in knee osteoarthritis in the journal Cartilage; results were previously presented in September 2025.
- The study showed the treatment was well tolerated, with no serious treatment-related safety issues reported.
- Patients reported reduced knee pain and improved joint function, supporting a potential disease-modifying effect.
- The highest dose showed sustained improvements in cartilage and bone tissue quality for up to two years, with signs of slowing cartilage breakdown.
- Publication increases visibility of the dataset for potential partners, strengthening the investment case for further development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
